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Single- and multiple-dose pharmacokinetics, pharmacodynamics, and 
safety of apixaban in healthy Chinese subjects [Corrigendum]
Cui Y, Song Y, Wang J, et al. Clinical Pharmacology: 
Advances and Applications. 2013;5(1):177–184.
Note that on page 182, Figure 3 should be corrected as   follows, 
with the line for mean anti-Xa activity extended through to 
72 hours post dose on Day 9, and the Day 1 plasma apixaban 
concentration-time profile rendering error bars and symbols 
more visually apparent.
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Figure 3 mean anti-Xa activity and plasma apixaban concentration versus time following single-dose administration 
(day 1) and at steady state (day 9). error bars show +1 standard deviation from the mean.